Q4 2024 Earnings Forecast for Evolus, Inc. (NASDAQ:EOLS) Issued By HC Wainwright

Evolus, Inc. (NASDAQ:EOLS) – Analysts at HC Wainwright lifted their Q4 2024 earnings per share estimates for Evolus in a research report issued to clients and investors on Thursday, October 3rd. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of $0.01 per share for the quarter, up from their prior estimate of ($0.01). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Evolus’ FY2026 earnings at $0.40 EPS, FY2027 earnings at $1.31 EPS and FY2028 earnings at $2.18 EPS.

A number of other analysts have also recently weighed in on EOLS. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. Barclays upped their price target on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research report on Friday, September 13th.

Evolus Stock Performance

Shares of NASDAQ:EOLS opened at $16.34 on Friday. The business’s fifty day moving average price is $15.13 and its two-hundred day moving average price is $13.27. Evolus has a fifty-two week low of $7.44 and a fifty-two week high of $17.70. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -15.56 and a beta of 1.31. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to analysts’ expectations of $65.06 million.

Hedge Funds Weigh In On Evolus

Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its stake in shares of Evolus by 84.2% during the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock valued at $5,683,000 after acquiring an additional 185,532 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Evolus during the first quarter valued at $1,907,000. Perceptive Advisors LLC lifted its stake in shares of Evolus by 166.8% during the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock valued at $41,735,000 after acquiring an additional 2,477,623 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Evolus by 5,627.2% during the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after acquiring an additional 930,566 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Evolus during the first quarter valued at $11,628,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Insiders Place Their Bets

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.